Background Infections are among the most important causes of morbidity and mortality in SLE patients . Despite the availability of newer therapeutic measures to improve clinical outcome in SLE patients, the incidence of infections as a cause of morbidity and mortality has not changed over the past 30 years , and infection is still considered as one of the leading causes of morbidity and mortality in SLE patients . Infection is responsible for approximately 25% of all deaths in patients with SLE, making it a leading cause of mortality in SLE .
Objectives To determine the prevalence of infections, to describe their sites, relation of infection to disease activity in this group of Egyptian Systemic lupus erythematosus (SLE) patients.
Methods Medical records of 175 Systemic lupus erythematosus (SLE) patients attending the Rheumatology & Rehabilitation Department, Cairo University hospital were reviewed retrospectively for the demographic information, clinical features of the disease, immune profile, laboratory features, systemic lupus erythematosus disease activity index (SLEDAI) and medical treatment with special reference to the relation of infection to disease activity in this group of Egyptian SLE patients. All of the patients fulfilled the updated American College of Rheumatology (ACR) revised criteria for the classification of SLE.
Results 87 patients (49.71%), experienced infection. The most common site of infection was the skin in 36% then UTI in 22%, chest in 15%. Highly significant statistical difference was found between infection and non infection group regarding (SLEDAI) P<0.001 (after regression analysis P=0.000).
Conclusions Disease activity is an important risk factor for infection in SLE patients.
Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, et al. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11(4):R109. doi: 10.1186/ar2764. Epub 2009 Jul 15.
Enberg G M, Kahn Ch M, Goity FC, et al. Infections in patients with Systemic Lupus Erythematosus. Rev Med Chil. 2009 Oct;137(10):1367-74.
Sciascia S, Ceberio L, Garcia-Fernandez C, et al. Systemic lupus erythematosus and infections: Clinical importance of conventional and upcoming biomarkers. Autoimmun Rev. 2012 Dec;12(2):157-63. doi: 10.1016/j.autrev.2012.03.009. Epub 2012 Apr 1.
Kamen DL. How can we reduce the risk of serious infection for patients with systemic lupus erythematosus?. Arthritis Res Ther. 2009;11(5):129.
Disclosure of Interest None declared